- Home
- SORA vs BOLD Comparison
SORA vs BOLD Comparison
Compare SORA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SORA | BOLD |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.2M | 60.8M |
| IPO Year | 2024 | 2024 |
Fundamental Metrics
Financial Performance| Metric | SORA | BOLD |
|---|---|---|
| Price | $2.22 | $2.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 72.2K | ★ 94.1K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $0.96 |
| 52 Week High | $6.99 | $3.16 |
Technical Indicators
Market Signals| Indicator | SORA | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 50.96 | 55.19 |
| Support Level | $2.07 | $2.74 |
| Resistance Level | $2.54 | $2.97 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 67.59 | 28.57 |
Price Performance
Historical ComparisonAbout SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.